Home Cart Sign in  
Chemical Structure| 1357389-11-7 Chemical Structure| 1357389-11-7

Structure of RGFP966
CAS No.: 1357389-11-7

Chemical Structure| 1357389-11-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

RGFP966 is specific inhibitor of HDAC3 with an IC50 of 0.08 μM and no effective inhibition of any other HDAC at concentrations up to 15 μM (measured by enzymatic activity of recombinant human HDACs).

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of RGFP966

CAS No. :1357389-11-7
Formula : C21H19FN4O
M.W : 362.40
SMILES Code : O=C(NC1=CC=C(F)C=C1N)/C=C/C2=CN(C/C=C/C3=CC=CC=C3)N=C2
MDL No. :MFCD26960954
InChI Key :BLVQHYHDYFTPDV-VCABWLAWSA-N
Pubchem ID :56650312

Safety of RGFP966

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of RGFP966

epigenetics

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HASMC 2 mM 48 h Inhibition of HASMC proliferation PMC10840433
Human kidney tubular HK2 cells 10 mg/kg 24 h To assess the effects of RGFP966 on luciferase activities linked to GPX4 promoter. PMC10638610
HK2 cells 10 μM 24 hours RGFP966 reduced TGFβ-induced α-SMA and collagen 1 expressions and alleviated Klotho suppression PMC7937860

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice AKI-CKD model mice induced by aristolochic acid or folic acid. Subcutaneous injection 10 mg/kg Total of 3 days, administered every other day. To mitigate ferroptotic and fibrotic renal injuries in the AKI-CKD mouse models. PMC10638610
C57Bl/6J mice Cocaine-induced conditioned place preference model Subcutaneous injection 3 mg/kg or 10 mg/kg Immediately after posttest 1 and posttest 2 RGFP966 facilitated the extinction of cocaine-induced conditioned place preference and prevented reinstatement of the behavior. PMC3574934
C57Bl/6J mice Retinal ischemia-reperfusion injury model Intraperitoneal injection 10 mg/kg Every 48 hours until day 7 RGFP966 treatment ameliorated the retinal neurodegeneration and thinning caused by IR injury, indicating neuroprotective effects of HDAC3 inhibition in retinal ischemia-reperfusion injury. PMC11241909
C57BL/6 mice UUO and AAN models Subcutaneous injection 10 mg/kg Every other day for 7 days RGFP966 significantly reduced renal fibrotic lesions in UUO and AAN mice and corrected the abnormal expressions of α-SMA, collagen 1, E-cadherin, and BMP-7 PMC7937860

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.76mL

0.55mL

0.28mL

13.80mL

2.76mL

1.38mL

27.59mL

5.52mL

2.76mL

References

 

Historical Records

Categories